Ultragenyx Pharmaceutical (LTS:0LIF) Long-Term Debt: $0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LIF Ultragenyx Pharmaceutical Inc LTS:0LIF
65 GF Score
Price $25.01
GF Value $46.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Long-Term Debt?

Ultragenyx Pharmaceutical LTS:0LIF -0.97% 65 Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0LIF with a GF Score™ of 65/100 and a GF Value™ of $46.14 (Possible Value Trap). The stock has 5 warning signs investors should review.

Ultragenyx Pharmaceutical's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.0 Mil.

Ultragenyx Pharmaceutical  (LTS:0LIF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ultragenyx Pharmaceutical Long-Term Debt Related Terms

Ultragenyx Pharmaceutical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Long-Term Debt Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0LIF
65GF Score
Ultragenyx Pharmaceutical Inc LTS:0LIF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.0 Mil mean?
Ultragenyx Pharmaceutical (LTS:0LIF) has a Long-Term Debt of $0.0 Mil as of Mar. 2026.
Is Ultragenyx Pharmaceutical's Long-Term Debt too high?
Ultragenyx Pharmaceutical's current Long-Term Debt is $0.0 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Long-Term Debt compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Long-Term Debt of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ultragenyx Pharmaceutical's current Long-Term Debt is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (LTS:0LIF) is currently considered Possible Value Trap. The stock's GF Value™ is $46.14, compared to a current price of $25.01 — trading 45.8% below its estimated fair value. The current Long-Term Debt is $0.0 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (LTS:0LIF), the current Long-Term Debt is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (LTS:0LIF) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $25.01 is trading 45.8% below its estimated GF Value™ of $46.14. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for LTS:0LIF:

  • Long-Term Debt: $0.0 Mil
  • GF Value™: $46.14 vs. price of $25.01 (45.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the LTS:0LIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
65GF Score

Get the complete analysis for LTS:0LIF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.01
Price
$46.14
GF Value